GoodRx (NASDAQ:GDRX) Reaches New 12-Month Low on Analyst Downgrade

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) reached a new 52-week low during mid-day trading on Wednesday after Citigroup lowered their price target on the stock from $10.00 to $7.00. Citigroup currently has a buy rating on the stock. GoodRx traded as low as $4.61 and last traded at $4.63, with a volume of 871841 shares traded. The stock had previously closed at $4.70.

A number of other research firms have also recently issued reports on GDRX. Barclays lowered their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday. UBS Group lowered their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research report on Friday, August 9th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research report on Friday, August 9th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.86.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 4.17% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Beacon Capital Management LLC bought a new position in GoodRx during the first quarter worth $28,000. nVerses Capital LLC acquired a new position in GoodRx during the third quarter worth $33,000. Plato Investment Management Ltd acquired a new position in GoodRx during the second quarter worth $43,000. Dark Forest Capital Management LP acquired a new position in GoodRx during the second quarter worth $86,000. Finally, EntryPoint Capital LLC raised its holdings in GoodRx by 165.2% during the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after buying an additional 11,548 shares during the last quarter. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Performance

The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company’s fifty day simple moving average is $6.76 and its two-hundred day simple moving average is $7.48. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -153.67, a P/E/G ratio of 3.24 and a beta of 1.39.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.